Indaptus Therapeutics, Inc. INDP
are a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy.
We have evolved from more than a century of immunotherapy advances. Our approach is based on the hypothesis that efficient activation
of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package
of immune system activating signals that can be administered safely intravenously. Our patented technology is composed of single strains
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| R&D | $9.3M | $7.3M | $7.6M | $6.3M | $2.5M | $2.7M | — |
| SG&A | $10.5M | $8.1M | $8.8M | $8.6M | $5.2M | $944.2K | — |
| Total operating expenses | $19.8M | $15.4M | $16.4M | $14.9M | $7.7M | $3.6M | — |
| Operating income | -$19.8M | -$15.4M | -$16.4M | -$14.9M | -$7.7M | -$3.6M | — |
| Pre-tax income | -$20.8M | -$15.0M | -$15.4M | -$14.3M | -$7.7M | -$3.6M | — |
| Income tax | $1.7K | $1.7K | $2.5K | $30 | $1.6K | $800 | — |
| Net income | -$20.8M | -$15.0M | -$15.4M | -$14.3M | -$7.7M | -$3.6M | — |
| EPS, basic | -21.58 | -44.96 | -1.83 | -1.73 | -1.89 | — | — |
| EPS, diluted | -21.58 | -44.96 | -1.83 | -1.73 | -1.89 | -1.84 | — |
| Shares, diluted (wtd. avg.) | $966.1K | $334.1K | $8.4M | $8.3M | $4.1M | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | $8.5M | $5.8M | $13.4M | $9.6M | $39.1M | $1.6M | — |
| Short-term investments | — | — | — | $16.8M | — | — | — |
| Total current assets | $9.3M | $6.6M | $14.0M | $27.2M | $40.4M | $1.7M | — |
| Property, plant and equipment | — | — | $735 | $2.0K | $3.8K | $1.3K | — |
| Total assets | $9.3M | $7.3M | $14.9M | $28.1M | $40.6M | $1.8M | — |
| Accounts payable | $544.1K | $870.2K | $806.0K | $1.4M | $2.5M | $156.0K | — |
| Total current liabilities | $6.2M | $3.4M | $2.8M | $3.4M | $4.6M | $2.0M | — |
| Total liabilities | — | $3.4M | $2.8M | $3.4M | $4.7M | $2.0M | — |
| Retained earnings | -$81.3M | -$60.4M | -$45.4M | -$30.0M | -$15.7M | -$8.0M | — |
| Total equity | $3.2M | $3.9M | $12.1M | $24.6M | $35.9M | -$237.7K | $3.2M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$14.8M | -$12.3M | -$13.4M | -$13.1M | -$11.3M | -$3.3M | — |
| Depreciation and amortisation | — | $735 | $1.3K | $1.8K | $1.4K | $852 | — |
| Stock-based compensation | $1.4M | $2.3M | $3.0M | $3.0M | $1.5M | $140.0K | — |
| Capital expenditure | — | — | — | — | $3.9K | — | — |
| Investing cash flow | — | — | $17.1M | -$16.4M | $447.7K | — | — |
| Financing cash flow | $17.5M | $4.7M | — | — | $48.3M | $1.2M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001493152-26-033545.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |